Grantham, Mayo, Van Otterloo & Co (GMO)’s Vanda Pharmaceuticals VNDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$107K Sell
21,737
-6,607
-23% -$35.5K ﹤0.01% 675
2026
Q2
$173K Buy
28,344
+12,022
+74% +$78.5K ﹤0.01% 650
2026
Q1
$113K Buy
+16,322
New +$126K ﹤0.01% 621
2021
Q4
– Sell
-13,100
Closed -$225K – 739
2021
Q3
$225K Buy
+13,100
New +$229K ﹤0.01% 661
2021
Q1
– Sell
-14,600
Closed -$192K – 945
2020
Q4
$192K Sell
14,600
-122,700
-89% -$1.48M ﹤0.01% 780
2020
Q3
$1.33M Sell
137,300
-29,300
-18% -$313K 0.01% 471
2020
Q2
$1.91M Buy
166,600
+146,600
+733% +$1.66M 0.01% 428
2020
Q1
$207K Buy
+20,000
New +$248K ﹤0.01% 700

Other funds holding VNDA

Grantham, Mayo, Van Otterloo & Co (GMO)'s VNDA Position: Q3 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) reduced its Vanda Pharmaceuticals (VNDA) stake by 23% in Q3 2026, selling an estimated $35.5K and leaving 21,737 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #675.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in VNDA in Q1 2020 and has held it in 8 quarters since. The position peaked at $1.91M in Q2 2020. 152 funds tracked by Wall St. Rank hold VNDA as of Q3 2026.

  • Grantham, Mayo, Van Otterloo & Co (GMO) held 21,737 shares of Vanda Pharmaceuticals worth $107K as of Q3 2026.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 6,607 Vanda Pharmaceuticals shares in Q3 2026, an estimated $35.5K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q3 2026, its #675 holding.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Vanda Pharmaceuticals in Q1 2020 and has held it in 8 quarters since.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Vanda Pharmaceuticals position peaked at $1.91M in Q2 2020.
  • 152 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2026, filed 13 Nov 2026.